Literature DB >> 21056886

Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study.

Ole-Petter R Hamnvik1, Xiaowen Liu, Michael Petrou, Huizhi Gong, John P Chamberland, Esther H Kim, Costas A Christophi, Stefanos N Kales, David C Christiani, Christos S Mantzoros.   

Abstract

We examined the relationship between serum levels of leptin-binding protein (soluble leptin receptor [sOB-R]) and leptin with metabolic parameters at baseline and prospectively at 2-year follow-up in young healthy men. A total of 916 eighteen-year-old men were examined at baseline, with a subgroup of 91 participants examined again 2 years later. Anthropometric and metabolic measurements were performed at baseline and at follow-up. In the cross-sectional study, levels of sOB-R were significantly inversely correlated with all baseline measures of obesity and metabolic risk factors (blood pressure, total and low-density lipoprotein cholesterol, and fasting glucose), and significantly positively correlated with high-density lipoprotein cholesterol. After correcting for age, smoking status, and waist-to-hip ratio, the inverse correlation remained statistically significant for all measures of adiposity, fasting glucose, and the metabolic syndrome score. Correlations for leptin were similar in magnitude but opposite in direction to correlations for sOB-R. In prospective analyses, baseline levels of sOB-R were predictive at 2-year follow-up of fasting glucose, the metabolic syndrome score, and measures of adiposity in both unadjusted and adjusted models. Similarly, leptin was predictive of fasting glucose, the metabolic syndrome score, adiposity, and systolic blood pressure. We confirm correlations of leptin and sOB-R levels with measures of adiposity and metabolic risk factors at baseline, and demonstrate for the first time prospectively the role of sOB-R as an independent, although weak, predictor of metabolic syndrome and fasting glucose in young men.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056886     DOI: 10.1016/j.metabol.2010.09.009

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

Review 1.  Gut hormones and leptin: impact on energy control and changes after bariatric surgery--what the future holds.

Authors:  Konstantinos Michalakis; Carel le Roux
Journal:  Obes Surg       Date:  2012-10       Impact factor: 4.129

2.  Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation, and lacks day/night variation in humans.

Authors:  John P Chamberland; Reena L Berman; Konstantinos N Aronis; Christos S Mantzoros
Journal:  Eur J Endocrinol       Date:  2013-09-13       Impact factor: 6.664

3.  Novel locus for fibrinogen in 3' region of LEPR gene in island population of Vis (Croatia).

Authors:  Željka Tomas; Matea Zajc Petranović; Tatjana Škarić-Jurić; Ana Barešić; Marijana Peričić Salihović; Nina Smolej Narančić
Journal:  J Hum Genet       Date:  2014-10-09       Impact factor: 3.172

Review 4.  Leptin in human physiology and pathophysiology.

Authors:  Christos S Mantzoros; Faidon Magkos; Mary Brinkoetter; Elizabeth Sienkiewicz; Tina A Dardeno; Sang-Yong Kim; Ole-Petter R Hamnvik; Anastasia Koniaris
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-07-26       Impact factor: 4.310

5.  Circulating clusterin (apolipoprotein J) levels do not have any day/night variability and are positively associated with total and LDL cholesterol levels in young healthy individuals.

Authors:  Konstantinos N Aronis; Maria T Vamvini; John P Chamberland; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2011-09-07       Impact factor: 5.958

Review 6.  Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.

Authors:  Jonathan G Owen; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

7.  Circulating alanine transaminase (ALT) and γ-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study.

Authors:  Xiaowen Liu; Ole-Petter R Hamnvik; John P Chamberland; Michael Petrou; Huizhi Gong; Costas A Christophi; David C Christiani; Stefanos N Kales; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-03-15       Impact factor: 8.694

8.  Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans.

Authors:  Maria T Vamvini; Konstantinos N Aronis; Grigorios Panagiotou; Joo Young Huh; John P Chamberland; Mary T Brinkoetter; Michael Petrou; Costas A Christophi; Stefanos N Kales; David C Christiani; Christos S Mantzoros
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

9.  Serum leptin is associated with cardiometabolic risk and predicts metabolic syndrome in Taiwanese adults.

Authors:  Wen-Cheng Li; Kuang-Yu Hsiao; I-Chuan Chen; Yu-Che Chang; Shih-Hao Wang; Kuan-Han Wu
Journal:  Cardiovasc Diabetol       Date:  2011-04-28       Impact factor: 9.951

Review 10.  Leptin as a modulator of neuroendocrine function in humans.

Authors:  Sami M Khan; Ole-Petter R Hamnvik; Mary Brinkoetter; Christos S Mantzoros
Journal:  Yonsei Med J       Date:  2012-07-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.